Eli Lilly has unveiled new Phase 4 data supporting the efficacy and safety of Taltz (ixekizumab) when compared to Janssen’s Tremfya (guselkumab), showing that the former met all primary and secondary endpoints in the treatment of moderate to severe plaque psoriasis (PsO).
The 1,027-participant trial is the first to directly compare an IL-17A inhibitor to an IL-23/p19 inhibitor using the Psoriasis Area Severity Index (PASI) 100 score as a primary endpoint to assess their efficacy.
![[branded content] De vijf belangrijkste customer experience trends voor 2024](https://www.pharmamarketeer.nl/wp-content/uploads/2024/04/customer-experience-80x60.jpg)
